Can a new pill ease the hardening skin of systemic sclerosis?

NCT ID NCT07745725

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This phase II trial is testing an experimental tablet called TollB-001 in adults with systemic sclerosis, a rare autoimmune disease that causes skin thickening and can affect internal organs. The study aims to see whether the drug can improve skin symptoms and overall well-being compared to a placebo. Participants will be randomly assigned to receive either TollB-001 or a placebo, and researchers will monitor safety and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TollB-001 tablets
What this could lead to
If TollB-001 proves effective, it could offer a new treatment option to slow or reduce skin thickening and improve quality of life for people with systemic sclerosis.
What could go wrong
This is an early-phase study with a small number of participants, so results may not hold up in larger trials. The drug may also cause side effects or prove no better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 102206, China

  • Toll Biotech, 2108-B007, No. 9 West Beisihuan Road, Haidian District, Beijing, People's Republic of China

    Beijing, Beijing Municipality, 100083, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.